- TRADE NAMES: AMG 510; Lumakras (Amgen)
- INDICATIONS:
Advanced or metastatic non-small cell lung cancer in patients with the KRAS p.G12C-mutation.
This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).
- CLASS: Ras–GTPase inhibitor
- HALF-LIFE: 5 hours
- FDA APPROVAL DATE: 05/28/2021
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
CYP3A4 inducers, CYP3A4 substrates, Digoxin, Famotidine, H2 receptor antagonists, Itraconazole, Metformin, Omeprazole, P-gp substrates, Proton pump inhibitors, Rifampin - PREGNANCY: No available data for use in pregnant women.
Please login to view the rest of this drug profile.
Page last updated 03/31/2024
